UroGen Pharma Ltd. (URGN) Debt Components
- 2026-06-30: Long-term Debt, Excluding Current MaturitiesUSD $188.73M; Long-term DebtUSD $200.00M; Long-Term Debt, Maturity, Year OneUSD $0.00; Long-Term Debt, Maturity, Year TwoUSD $0.00.
- 2026-03-31: Long-term Debt, Excluding Current MaturitiesUSD $189.53M; Long-term DebtUSD $200.00M; Long-Term Debt, Maturity, Year OneUSD $0.00; Long-Term Debt, Maturity, Year TwoUSD $0.00.
- 2025-12-31: Long-term Debt, Excluding Current MaturitiesUSD $122.21M; Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m).
- 2025-12-31: Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD $125.00M; Long-Term Debt, Maturity, Year OneUSD $0.00; Long-Term Debt, Maturity, Year TwoUSD $93.75M.
UroGen Pharma Ltd. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, after Year Five USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Long-term Debt, Gross USD | Debt Instrument, Face Amount USD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $188.73M | $200.00M | $0.00 | $0.00 | $0.00 | $150.00M | $50.00M | (m) | $0.00 | (m) | (m) |
| 2026-03-31 | $189.53M | $200.00M | $0.00 | $0.00 | $0.00 | $150.00M | $50.00M | (m) | $0.00 | (m) | (m) |
| 2025-12-31 | $122.21M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $125.00M | $0.00 | $93.75M | $31.25M | $0.00 | $0.00 | $0.00 | (m) | (m) | (m) |
| 2025-09-30 | $122.11M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $122.51M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $122.11M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $121.73M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $121.71M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $97.81M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $97.59M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $98.55M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $98.52M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $98.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $97.94M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $97.54M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $71.87M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $71.20M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $70.80M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $70.80M | $75.00M |
| 2021-12-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |